Jim Cramer breaks down the potential behind struggling shipping giant UPS.
Canopy Growth has been granted a license by New York State to process and produce hemp.
Jan 11- Eli Lilly and Co remains in the hunt for cancer drugs even after announcing an $8 billion purchase of Loxo Oncology this week, but it plans to remain on the sidelines when it comes to two of the hottest areas of drug development. Lilly Chief Executive Dave Ricks told Reuters that as the company looks for deals to enhance its pipeline of future treatments it...
Privateer Holdings says it "strongly believes in Tilray's long-term global growth strategy and pioneering role" in legal cannabis.
Star investor Jeff Vinik, who just announced the revival of his hedge fund, doesn't see any money in cannabis stocks.
Canopy Growth shares surged 13 percent after Piper Jaffray initiates coverage of the cannabis industry, joining a growing list of brokerages watching the space.
FDA Commissioner Scott Gottlieb's keynote address Tuesday was delivered via video conference from Washington, D.C., to thousands of bankers and health executives, and his audio cut out just as he was making a key point on teen nicotine use.
Jim Cramer and Allergan Chairman, President and CEO Brent Saunders discuss how the pharmaceutical company will tackle Wall Street pessimism.
Wall Street's top cannabis analyst believes U.S. marijuana sales will jump to $80 billion and expects Canopy and Tilray to outperform.
Jim Cramer speaks to Bausch Health Companies Chairman and CEO Joseph Papa about his company's turnaround, competition and 2019 prospects.
Jim Cramer explains why it might be worth picking up shares of Micron now despite a possible negative quarter on the horizon.
Jim Cramer sits down with Amgen Chairman and CEO Bob Bradway to hear about the company's recent price cut for one of its key drugs.
Jim Cramer and Novartis CEO Vas Narasimhan discuss how the drugmaker is refocusing its business to leverage new-age treatments and potential cures.
Jim Cramer says leading drugmakers are innovating more than ever before and many of their stocks are worth owning.
Jan 3- Bristol-Myers Squibb Co's announcement that it would buy Celgene Corp for $74 billion has raised investors' hopes that a wave of consolidation among drugmakers could be coming. RBC analyst Brian Abrahams said in a research note on Thursday that Incyte is an acquisition target because it is undervalued and has an oncology and inflammation pipeline.
Jan 3- Bristol-Myers Squibb Co said on Thursday it would buy Celgene Corp for about $74 billion, combining two of the world's largest cancer drug businesses in the biggest pharmaceutical deal ever. Both Bristol-Myers and Celgene face separate challenges, and some Wall Street analysts questioned whether the combination- which the companies said would create...
Jan 3- Bristol-Myers Squibb Co said on Thursday it would buy Celgene Corp for about $74 billion, creating a major pharma company with several blockbuster cancer drugs as competition in the immunotherapy space heats up. The deal will create a company with nine treatments bringing in more than $1 billion in annual sales and a significant potential for growth in...
Jan 3- Bristol-Myers Squibb Co said on Thursday it would buy Celgene Corp for about $74 billion, creating a pharma company with several blockbuster cancer drugs and making it one of the biggest mergers on record in the sector. Celgene shareholders will receive one Bristol-Myers Squibb share and $50 in cash for each share held, or $102.43 per share, a premium of...
PARIS, Dec 26- The U.S. Food and Drug Administration approved Sanofi's new pediatric vaccine immunizing children against six diseases, the French pharmaceutical lab said on Wednesday. Sanofi developed the new vaccine, dubbed Vaxelis, in partnership with Merck. Vaxelis is designed for children aged 6 weeks to 4 years old and is designed to keep them from...
PARIS, Dec 26- The U.S. Food and Drug Administration approved Sanofi's new paediatric vaccine immunizing children against six diseases, the French pharmaceutical lab said on Wednesday. Sanofi developed the new vaccine, dubbed Vaxelis, in partnership with Merck. Vaxelis is designed for children aged 6 weeks to 4 years old and is designed to keep them from...
Data also provided by 
